Compositions and methods for tumor transduction
AssigneeAleta Biotherapeutics Inc.
InventorsRoy Lobb, Paul Rennert
Life of this patent
Estimating the term…
Abstract
The invention relates to cancer therapeutics, in particular, the system of making cancer cells more susceptible to effector cells by introduction of cellular therapy targets into the cancer cells.
Claims29
1-32. (canceled)
An adenoviral vector, comprising a nucleotide sequence encoding a fusion protein comprising (a) an antibody, or antigen-binding fragment thereof, that binds a tumor antigen;
- and (b) a polypeptide target for a cellular therapeutic, antibody, or antibody-drug conjugate.
An oncolytic viral vector, comprising a nucleotide sequence encoding a fusion protein comprising (a) an antibody, or antigen-binding fragment thereof, that binds a tumor antigen;
- and (b) a polypeptide target for a cellular therapeutic, antibody, or antibody-drug conjugate.
A method of treating a subject having a tumor, comprising administering to the subject an oncolytic viral vector comprising a nucleotide sequence encoding a fusion protein comprising (a) an antibody, or antigen-binding fragment thereof, that binds a tumor antigen;
- and (b) a polypeptide target for a cellular therapeutic, antibody, or antibody-drug conjugate.
Dependencies are inferred from the claim text.